San Mateo, Calif., United States: BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to
San Mateo, Calif., United States: 5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression
Basel, Switzerland & San Mateo, Calif., United States: New name reflects Company’s bold vision to eradicate cancer by harnessing the
San Mateo, Calif., United States: Continued financial progress with $1 billion in quarterly total revenue, reduced GAAP loss and
San Mateo, Calif., United States: Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with
San Mateo, Calif., United States: BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to
San Mateo, Calif., United States: BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the
Socially Bharat is your comprehensive source for Social news, NGO’s, and expert insights from across India.
Copyright© 2025 Creative Bharat Powered By A Buzz Company